Clinical trial
A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
NCT06932562 is registered in ClinicalTrials.gov with European Myeloma Network B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Open-Label, Controlled Phase 3 Study of Comparing Daratumumab, Lenalidomide and Dexamethasone Induction Followed by Linvoseltamab Versus Continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
- Lead sponsor
- European Myeloma Network B.V.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 23, 2025
- Completion date
- December 31, 2036
- Enrollment
- 1,000 (estimated)
- Sites
- 59
Conditions
As the registry lists them; a condition with its own page is linked.